A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Moderna is the only company in its peer group burning cash at an alarming rate. Click here to read more about MRNA stock and ...

The LNP-mRNA modality is a novel approach that uses lipid nanoparticles to deliver messenger RNA into cells. The mRNA acts as ...

Discover how scientists developed a COVID-19 vaccine in record time using mRNA technology, leading to improved public health ...

US mRNA specialist Moderna demonstrated substantial R&D investment and progress in the UK, two years since signing its ...

Bird flu isn’t part of the “quad-demic” of viruses circulating through the country this winter—COVID, seasonal flu ... the ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

The mRNA technology behind the Pfizer and Moderna vaccines are groundbreaking, but their potential goes way beyond COVID-19. They have the ability to help the body fight a multitude of diseases, from ...

While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

Moderna, Inc. (NASDAQ ... provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats CAMBRIDGE ...

Volunteers in north Wales are among 25,000 people taking part in a global trial to find a vaccine against the symptoms of the ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...